The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and... Read More

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs MILAN , June 15 , 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today new results from the Phase 2 RedirecTT-1 study evaluating the... Read More

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose MILAN , June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an... Read More

Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation MILAN , June 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new Phase 1b data showing encouraging... Read More

TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA ® -treated patients across both dose groups achieved ACR50 at Week 24 Improvement in both joint and skin symptoms reinforce TREMFYA ® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA , June 11, 2025... Read More

NEW BRUNSWICK, N.J. / Jun 10, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have Daniel join Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “He is an exceptional leader with deep financial expertise and understanding of... Read More

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel... Read More

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI ® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b /2 CARTITUDE-1 study demonstrating 33... Read More

More than half of patients maintained minimal residual disease (MRD) negativity (10 -5 ) with DARZALEX FASPRO ® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10 −5 ) and improved PFS with DARZALEX FASPRO ® in transplant-ineligible newly diagnosed patients CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data... Read More

Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of care CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind,... Read More

NEW BRUNSWICK, N.J. / May 28, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16 th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and... Read More

NEW BRUNSWICK, N.J. / May 21, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28 th , 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com . An archived edition of... Read More

ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO ® would be the first treatment to potentially delay or prevent progression to multiple myeloma RARITAN, N.J. , May 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2)... Read More

NEW BRUNSWICK, N.J. / May 14, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46 th Annual Global Healthcare Conference on Wednesday, June 11 th , 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com . The... Read More

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill SPRING HOUSE, Pa. , May 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data... Read More

New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges NEW BRUNSWICK, N.J. / May 08, 2025 / Business Wire / Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts are part of J&J CareCommunity, a new social impact platform that focuses the resources... Read More

TREMFYA ® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA ® in Crohn's disease SAN DIEGO , May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA ®... Read More

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif. , May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA ® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis... Read More

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study... Read More

NEW BRUNSWICK, N.J. / Apr 28, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28 th , 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com . An archived edition of... Read More

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today... Read More

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from Cohort... Read More

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer RARITAN, N.J. , April 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that new data from... Read More

NEW BRUNSWICK, N.J. / Apr 16, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20 th . Management will participate in a Fireside Chat at 1:35 p.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com . The audio... Read More

NEW BRUNSWICK, N.J. / Apr 15, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend... Read More

2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn’s disease, data for RYBREVANT/LAZCLUZE overall... Read More

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 SPRING HOUSE, Pa. , April 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:... Read More

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension phase Up to 128 weeks and 180 patient years of follow-up in the open-label extension a confirm a safety profile consistent with the Phase 3 Vivacity-MG3 study 45% of the patients receiving steroids at open-label extension... Read More

NEW BRUNSWICK, N.J. / Apr 07, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will present at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13 th , 2025. Management will participate in a Fireside Chat at 1:40 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com . An archived edition of the session... Read More

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA ® as a first-line treatment option for patients with active psoriatic arthritis SPRING HOUSE, Pa. , April 4, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ)... Read More

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA ® as adjunctive treatment for major depressive disorder; if approved, has potential to become a new... Read More

NEW BRUNSWICK, N.J. / Apr 01, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies’ shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025. The transaction is expected to accelerate 2025 sales growth for... Read More

Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution NEW BRUNSWICK, N.J. / Mar 31, 2025 / Business Wire / Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE: JNJ) (the “Company”) subsidiary Red River Talc LLC (“Red River”) to confirm... Read More

Median overall survival not yet reached with projected improvement of more than one year versus osimertinib RARITAN, N.J. , March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™... Read More

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMG a score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADL b and QMG scores from the ongoing open-label extension (OLE) of the... Read More

Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs Includes four planned new manufacturing facilities, with ground-breaking today in North Carolina on $2 billion+ facility Total Company U.S. economic impact estimated to be more than $100 billion per year NEW BRUNSWICK, N.J. / Mar 21, 2025 / Business Wire / Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s... Read More

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA ® is the only IL-23i to show superiority versus STELARA ® in all pooled endoscopic endpoints within a double-blinded registrational trial TREMFYA ® approval in Crohn's disease builds upon recent ulcerative colitis FDA approval,... Read More

Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regimen meets primary endpoint and enhances patient experience RARITAN, N.J. , March 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that new data from its industry-leading oncology pipeline will be presented... Read More

Sjögren's disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks the fourth nipocalimab FDA Fast Track designation SPRING HOUSE, Pa. , March 18, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational... Read More

Phase 3 MARIPOSA study showed LAZCLUZE ® plus RYBREVANT ® significantly improved progression-free survival, reducing the risk of disease progression or death by 30 per cent versus osimertinib alone. 1 TORONTO , March 10, 2025 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for LAZCLUZE ® (lazertinib) in combination with RYBREVANT ® (amivantamab) for the... Read More

Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program Icotrokinra demonstrates potential to offer therapeutic benefit and... Read More

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotrokinra achieved co-primary endpoints and showed... Read More

NEW BRUNSWICK, N.J. / Mar 05, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15 th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and... Read More

Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine NEW BRUNSWICK, N.J. / Mar 04, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson... Read More

Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction SPRING HOUSE, Pa. , Feb. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from the Phase... Read More

Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions SPRING HOUSE, Pa. , Feb. 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an... Read More

NEW BRUNSWICK, N.J. / Feb 03, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will present at the 45 th Annual TD Cowen Healthcare Conference on Tuesday, March 4 th , 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com . An archived edition of the session... Read More

Underscores the urgent need for improved diagnosis and clinical management of psoriasis in patients with skin of colour and enhanced treatment standards TORONTO , Jan. 23, 2025 /CNW/ - Johnson & Johnson (NYSE: JNJ) is proud to announce a Canadian first: the publication of a consensus statement titled, "Optimizing the management of psoriasis in patients with skin of colour: a Canadian Delphi consensus." This groundbreaking... Read More

The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a sustained reduction in autoantibody levels, one of the underlying causes of gMG, by up to 75% over a period of 24 weeks The investigational therapy was recently granted U.S. FDA Priority Review for the treatment of gMG SPRING HOUSE, Pa. , Jan. 23,... Read More

2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%* 2024 Fourth-Quarter Earnings per share (EPS) of $1.41 and Adjusted EPS of $2.04, both include $(0.22) due to acquired IPR&D charges related to V-Wave acquisition 2024 Full-Year reported sales growth of 4.3% to $88.8 Billion with operational growth of 5.9%* and adjusted operational... Read More

Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO ® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours 1 SPRAVATO ® alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, with numerical improvements across all 10 MADRS... Read More

Phase 3 MARIPOSA-2 study showed RYBREVANT ® in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone. 1 TORONTO , Jan. 16, 2025 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for RYBREVANT ® (amivantamab for injection) in combination with carboplatin and pemetrexed... Read More

Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent 1 RARITAN, N.J. , Jan. 15, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients with... Read More

Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA ® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA ® has potential to become a standard of care for most common depressive disorders CAPLYTA ®... Read More

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4 SPRING HOUSE, Pa. , Jan. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review... Read More

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's commitment to Alzheimer's disease development and the potential of its precision approach TITUSVILLE, N.J. , Jan. 8, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration... Read More

Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer RARITAN, N.J. , Jan. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating... Read More

NEW BRUNSWICK, N.J. / Jan 02, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2025 of $1.24 per share on the company’s common stock. The dividend is payable on March 4, 2025 to shareholders of record at the close of business on February 18, 2025. The ex-dividend date is February 18, 2025. About Johnson & Johnson At Johnson... Read More

NEW BRUNSWICK, N.J. / Dec 12, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 th , at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time). This live audio webcast will be available to investors and other... Read More

NEW BRUNSWICK, N.J. / Dec 10, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22 nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and... Read More

89 percent of patients evaluable for MRD assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months Results add to the overall survival (OS) benefits recently presented, as the first and only cell therapy to significantly extend OS versus standard therapies in multiple myeloma SAN DIEGO , Dec. 9, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today new results from the Phase 3... Read More

Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and the uncertainty of current treatment approaches used to manage the condition There are no FDA-approved therapies indicated for wAIHA, and patients living with this condition need targeted treatment options with a proven safety and efficacy profile Johnson & Johnson is... Read More

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10 -6 ) with DARZALEX FASPRO ® were progression free at 4.5 years Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations disproportionately impacted by multiple myeloma SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data... Read More

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and... Read More

First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) significantly delayed progression... Read More

Applications filed for TREMFYA ® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis SPRING HOUSE, Pa. , Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ® (guselkumab) for the treatment of children 6 years and older... Read More

Following recent U.S. FDA approval of TREMFYA ® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offers choice of subcutaneous or intravenous induction in UC Submission is supported by the Phase 3 ASTRO study, which achieved the primary endpoint of clinical remission at Week 12 and met all secondary endpoints in adults with... Read More

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI ® reduced the risk of disease progression or death by 74 per cent compared to standard of care. 1 TORONTO , Nov. 21, 2024 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI ® (ciltacabtagene autoleucel) for the treatment of adult... Read More

More than 90 presentations of clinical trial and real-world data highlight potentially practice-changing evidence and commitment to pioneer the next wave of therapies for patients with hematologic malignancies RARITAN, N.J. , Nov. 19, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented... Read More

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 Comprehensive results are being prepared for presentation at upcoming medical congresses SPRING HOUSE, Pa. , Nov. 18, 2024 /PRNewswire/ -- Johnson &... Read More

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS... Read More

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study A greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants on average who received nipocalimab 15 mg/kg compared to participants who... Read More

If approved, DARZALEX FASPRO ® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage RARITAN, N.J. , Nov. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the submission of regulatory applications to the U.S. Food and Drug... Read More

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA ® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions and a plenary session Results from the Phase 2 DAHLIAS study of nipocalimab in SjD show nipocalimab met the primary endpoint with a reduction in ClinESSDAI score from baseline and other key efficacy endpoints at Week 24... Read More

BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- I novalon , a leading provider of cloud-based software solutions empowering data-driven healthcare, welcomed industry trailblazers and visionary executives to the stage at Empower 2024 , sparking meaningful conversations with leaders from every corner of healthcare. The annual summit, focused on the intersection of healthcare and technology, welcomed attendees in Washington,... Read More

A greater number of patients treated with subcutaneous TREMFYA ® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA ® could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (CD), pending FDA approval PHILADELPHIA , Oct. 28, 2024 /PRNewswire/ -- Johnson... Read More

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson & Johnson launches library of clinical images from Phase 3b VISIBLE study to enhance clinical decision making for people across all skin tones living with moderate to severe plaque psoriasis LAS VEGAS , Oct. 25, 2024 /PRNewswire/... Read More

New five-year data reinforce long-term safety and efficacy of SPRAVATO ® (esketamine) in patients with inadequate response to two or more oral antidepressants (treatment-resistant depression) 23 abstracts highlight data from Company's robust portfolio and pipeline, including clinical insights on major depressive disorder and the significant burden of anhedonia and insomnia symptoms Large real-world analysis highlights the... Read More

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied SAVANNAH, Ga. , Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChR a positive adolescents (aged 12 – 17 years) living with... Read More

NEW BRUNSWICK, N.J. / Oct 15, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024. About Johnson & Johnson At... Read More

2024 Third-Quarter reported sales growth of 5.2% to $22.5 Billion with operational growth of 6.3%* and adjusted operational growth of 5.4%* 2024 Third-Quarter Earnings per share (EPS) of $1.11 decreasing by 34.3% due to a one-time special charge and acquired IPR&D. Adjusted EPS of $2.42 decreasing by 9.0%* with acquired IPR&D impacting results approximately 1,900 basis points Significant pipeline progress including approvals... Read More

NEW BRUNSWICK, N.J. / Oct 10, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Stifel 2024 Healthcare Conference on Monday, November 18 th , at the Lotte New York Palace in New York. Michael Bodner, Group President, Heart Recovery & Circulatory Restoration , will represent the Company in a session scheduled at 10:55 a.m. (Eastern Time). This live audio webcast will be available to investors and... Read More

TREMFYA ® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease TREMFYA ® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved... Read More

Adds V-Wave’s Novel and Minimally Invasive Ventura ® Interatrial Shunt to the Johnson & Johnson MedTech Portfolio Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular Disease NEW BRUNSWICK, N.J. / Oct 09, 2024 / Business Wire / Johnson & Johnson 1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options... Read More

NEW BRUNSWICK, N.J. / Oct 04, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12 th , at the InterContinental Boston in Boston, MA. Biljana Naumovic, President, Solid Tumor, U.S. Oncology and Mark Wildgust, Vice President, Global Medical Affairs Oncology , will represent the Company in a session scheduled at 10:30 a.m. (Eastern Time).... Read More

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA ® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, Portugal , Oct. 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA ® (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to... Read More

Results from CEPHEUS study highlight DARZALEX FASPRO ® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility New indication would be the first FDA-approved treatment regimen for newly diagnosed multiple myeloma based on a study with MRD-negativity as the primary endpoint RARITAN, N.J. , Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today... Read More

The new full visual range IOL* 1 delivers exceptional distance vision 2 and 14% smaller readable print size vs PanOptix 3 † . 93% of patients become free from glasses at all distances. #4 ‡ TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes. 5¶ JACKSONVILLE, Fla. , Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson § , a global leader... Read More

45 percent reduction in risk of death achieved with CARVYKTI ® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI ®... Read More

Minimal residual disease (MRD)-negativity rate of 10 -5 more than doubled by 12 months with DARZALEX FASPRO ® in maintenance therapy compared to lenalidomide alone, resulting in improvement in 30-month progression-free survival RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from three studies highlighting clinical efficacy of DARZALEX ® (daratumumab) and DARZALEX FASPRO ®... Read More

Study of the first and only subcutaneous quadruplet regimen demonstrates 60.9 percent improvement in minimal residual disease (MRD)-negativity and 43 percent reduction in the risk of progression or death Phase 3 CEPHEUS study results presented in late-breaking oral presentation at the International Myeloma Society (IMS) Annual Meeting RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced... Read More

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY ® and TECVAYLI ® monotherapies RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever bispecific antibody combination of TALVEY ® (talquetamab-tgvs), the first and only FDA-approved... Read More

Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody Safety profile, including infection rates, similar to TALVEY ® and DARZALEX FASPRO ® monotherapies RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced updated results from the... Read More

Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan Red River Increased its Settlement Commitment by $1.75 Billion to Approximately $8 Billion NEW BRUNSWICK, N.J. / Sep 20, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the “Company”) announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 bankruptcy case... Read More

Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT ® this year, with four indications overall RARITAN, N.J. , Sept. 17, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT ® (amivantamab-vmjw) in combination with standard of care chemotherapy (carboplatin and... Read More

TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, Spain , Sept. 16, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with investigational TAR-200 plus cetrelimab (CET) achieved nearly double the... Read More

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BARCELONA, Spain , Sept. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational TAR-200 for the... Read More

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT ® beyond lung cancer BARCELONA , Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b /2 OrigAMI-1 study, which showed RYBREVANT ® (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated... Read More

Post-progression outcomes showed significant and sustained improvement for RYBREVANT ® plus standard of care versus chemotherapy alone BARCELONA , Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT ® (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with... Read More

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program 1,2,3,4,5 TREMFYA ® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis HORSHAM, Pa. , Sept. 11, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today... Read More

Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ® , a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO , Sept. 10, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of... Read More

New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT ® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy Results from an interim analysis featured in late-breaker oral presentation at WCLC SAN DIEGO , Sept. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced longer follow-up data from the landmark Phase 3 MARIPOSA study which... Read More

NEW BRUNSWICK, N.J. / Sep 05, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15 th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and... Read More

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ SPRING HOUSE, Pa. , Aug. 29, 2024... Read More

Four RYBREVANT ® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer RARITAN, N.J. , Aug. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company's industry-leading solid tumor portfolio and pipeline will be featured at the 2024... Read More

NEW BRUNSWICK, N.J. / Aug 26, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that Dr. Peter M. Fasolo will retire from his position as Executive Vice President, Chief Human Resources Officer at the end of this year, following 16 years of leadership and service to the Company. Throughout his distinguished career, Dr. Fasolo has worked with the organization’s Board of Directors and partnered with three... Read More

V-Wave’s Novel and Minimally Invasive Interatrial Shunt is Designed to Treat Heart Failure and Addresses Significant Treatment Gap Device Further Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular NEW BRUNSWICK, N.J. / Aug 20, 2024 / Business Wire / Johnson & Johnson 1 (NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on... Read More

RYBREVANT ® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT ® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of response RARITAN, N.J. , Aug. 20, 2024 /PRNewswire/ --... Read More

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine transfusion (IUT) The AZALEA Phase 3 clinical study is currently enrolling patients: Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN)... Read More

Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO ® showed 60 percent reduction in risk of disease progression or death New regimen solidifies DARZALEX FASPRO ® as a foundational frontline therapy in multiple myeloma with potential to significantly delay disease progression HORSHAM, Pa. , July 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug... Read More

NEW BRUNSWICK, N.J. / Jul 29, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5 th , at the Encore Boston Harbor, Evertte, MA. Tim Schmid, Executive Vice President, WorldWide Chairman, MedTech will represent the Company in a session scheduled at 11:00 am (Eastern Time). This live audio webcast will be available to investors and other... Read More

NEW BRUNSWICK, N.J. / Jul 23, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4 th , held at the New York Marriott Marquis, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer and John Reed, Executive Vice President, Innovative Medicine, R&D will represent the Company in a session scheduled at 10:45 am... Read More

Phase 4 SPRAVATO ® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of real-world use that reinforce the safety and efficacy of SPRAVATO ® TITUSVILLE, N.J. , July 22, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a... Read More

NEW BRUNSWICK, N.J. / Jul 17, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is August 27, 2024. About Johnson & Johnson At Johnson... Read More

2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%* Significant new product pipeline progress including TREMFYA IBD and... Read More

NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases NEW BRUNSWICK, N.J. / Jul 11, 2024 / Business Wire / Johnson & Johnson 1 (NYSE: JNJ) announced today that it has successfully completed the acquisition of Yellow Jersey, a... Read More

Phase 3 PAPILLON study showed RYBREVANT ® in combination with carboplatin and pemetrexed significantly improved progression-free survival, reducing the risk of disease progression or death by 60 per cent versus carboplatin and pemetrexed alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations. 1 TORONTO , July 3, 2024 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada,... Read More

CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN, N.J. , July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI ® (ciltacabtagene autoleucel;... Read More

First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADL a ) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+ HELSINKI , June 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG).... Read More

Acquisition includes two pre-clinical bispecific antibodies targeting proven disease pathways, offering the potential to transform the treatment paradigm for patients living with atopic dermatitis and other immune-mediated diseases NEW BRUNSWICK, N.J. / Jun 21, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held... Read More

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA ® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn's disease GALAXI includes data demonstrating superior outcomes for... Read More

TREMFYA ® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa. , June 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA ® (guselkumab) subcutaneous (SC) induction therapy in adult patients with moderately to severely active Crohn's disease. 1 The study met both co-primary... Read More

Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab Longer overall survival, progression-free survival and duration of response also observed with subcutaneous amivantamab RARATIN, N.J. , June 17, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a Biologics License Application... Read More

Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments VIENNA , June 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated... Read More

24-month overall survival rate of 67 percent achieved with TALVEY ® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study MADRID , June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated... Read More

Strengthens Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Creates Greater Opportunity to Transform the Treatment Landscape for Cardiovascular Disease NEW BRUNSWICK, N.J. / May 31, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit... Read More

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN,... Read More

The Company 1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary 2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) NM26 has the potential to offer distinctive benefits versus existing treatments and address key unmet needs for AD patients Johnson & Johnson is committed to... Read More

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD) Includes bispecific antibodies targeting proven disease pathways and offers the potential to provide best-in-disease therapeutics for people with moderate to severe AD and asthma These pipeline additions demonstrate the Company’s strategic approach to build a portfolio of... Read More

NEW BRUNSWICK, N.J. / May 08, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference on Wednesday, June 12 th , at the Loews Miami Beach Hotel, Miami Beach, Florida. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine and John Reed, Executive Vice President, Innovative Medicine R&D will represent the Company in a... Read More

The Plan would resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States NEW BRUNSWICK, N.J. / May 01, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced a proposed Plan of Reorganization (the “Plan”) by its subsidiary, LLT Management LLC ("LLT"), for the comprehensive and final resolution of all current and future claims related to ovarian... Read More

NEW BRUNSWICK, N.J. / Apr 22, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein’s 40 th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29 th , at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm (Eastern Time). This live audio webcast will be available to investors and... Read More

NEW BRUNSWICK, N.J. / Apr 16, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62 nd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend... Read More

2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%* Adjusted operational growth excluding COVID-19 Vaccine of 7.7%* 2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%* Company increasing the midpoint for Full-Year 2024 operational sales 5 and adjusted operational EPS guidance NEW... Read More

NEW BRUNSWICK, N.J. / Apr 08, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15 th , at the InterContinental Barclay Hotel, New York. Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will represent the Company in a session scheduled at 11:00 am (Eastern Time). This live audio webcast will be available to... Read More

Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with CARVYKTI ® in 1-3 prior lines of therapy reduced the risk of disease progression or death by 59 percent compared to standard therapies HORSHAM, Pa. , April 5, 2024... Read More

Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss... Read More

NEW BRUNSWICK, N.J. / Apr 04, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash. TRC Capital Investment’s offer price of $151.23 per share is approximately 4.12% lower than the... Read More

NEW BRUNSWICK, N.J. / Apr 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14 th , at the Encore Hotel, Las Vegas, Nevada. John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time). This live audio webcast will be available to investors and other interested... Read More

NEW BRUNSWICK, N.J. / Mar 11, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16 th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and... Read More

Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics NEW BRUNSWICK, N.J. / Mar 07, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary... Read More

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT ® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations National Comprehensive Cancer Network ® (NCCN ® ) updated its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) to recommend... Read More

Biweekly dosing with TECVAYLI ® , the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility HORSHAM, Pa. , Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in... Read More

NEW BRUNSWICK, N.J. / Feb 14, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13 th , at the Loews Miami Beach Hotel, Miami Beach, FL. Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision will represent the Company in a session scheduled at 10:45 a.m. (Eastern Time). This live audio webcast will be available to... Read More

NEW BRUNSWICK, N.J. / Feb 12, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12 th , at the Fontainebleau Miami Beach, FL. Joe Wolk, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 1:00 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested... Read More

NEW BRUNSWICK, N.J. / Feb 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45 th Annual Institutional Investors Conference on Tuesday, March 5 th , at the JW Marriott Orlando Grande Lakes, Orlando, FL. Ahmet Tezel, Company Group Chairman, MedTech R&D will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time). This live audio webcast will be available to... Read More

2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2%* and adjusted operational growth of 5.7%*. Operational growth excluding COVID-19 Vaccine of 10.9%* 2023 Fourth-Quarter Earnings per share (EPS) of $1.70 increasing 39.3% and adjusted EPS of $2.29 increasing by 11.7%* 2023 Full-Year reported sales growth of 6.5% to $85.2 Billion with operational growth of 7.4%* and adjusted... Read More

Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics NEW BRUNSWICK, N.J. / Jan 08, 2024 / Business Wire / Johnson & Johnson... Read More

NEW BRUNSWICK, N.J. / Jan 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2024 of $1.19 per share on the company’s common stock. The dividend is payable on March 5, 2024 to shareholders of record at the close of business on February 20, 2024. The ex-dividend date is February 16, 2024. About Johnson & Johnson At Johnson... Read More

NEW BRUNSWICK, N.J. / Dec 11, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23 rd to review fourth-quarter results. Joaquin Duato, Chairman and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. Investors and other interested parties... Read More

NEW BRUNSWICK, N.J. / Dec 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 th , at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time) This live audio webcast will be available to investors and other... Read More

Provides long-term operational sales outlook, including: Enterprise Compound Annual Growth Rate (CAGR) of 5-7% 1* for 2025-2030 Innovative Medicine CAGR of 5-7% 1* for 2025-2030; expects 10+ assets with peak year sales (PYS) 2 potential of $5B+* and another 15+ assets with PYS 2 potential of $1-5B* MedTech in the upper range of its markets, which are growing 5-7% 3 for 2022-2027, with one third of 2027 sales coming from new... Read More

NEW BRUNSWICK, N.J. / Nov 30, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors. “Mr. Woods is an exceptional addition to Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Mr. Woods has an impressive career of leading... Read More

Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth MedTech segments NEW BRUNSWICK, N.J. / Nov 30, 2023 / Business Wire / Johnson & Johnson MedTech 1 today announced the completion of the acquisition 2 of Laminar, Inc., a privately-held medical device company focused on... Read More

NEW BRUNSWICK, N.J. / Nov 16, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the ‘Company’) will hold an Enterprise Business Review for the investment community on Tuesday, December 5, 2023. During the event, Company leaders will share a detailed review of the Innovative Medicine and MedTech businesses and their respective pipelines as well as discuss the Company’s long-term strategy to deliver sustained growth and... Read More

NEW BRUNSWICK, N.J. / Oct 23, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the Company) announced today that Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, informed the company on October 20, 2023, that she is stepping down from her position to pursue other opportunities. Ms. McEvoy will remain with the Company into Q1 2024 to support a successful transition. Tim Schmid has been appointed... Read More

NEW BRUNSWICK, N.J. / Oct 19, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2023 of $1.19 per share on the company’s common stock. The dividend is payable on December 5, 2023 to shareholders of record at the close of business on November 21, 2023. The ex-dividend date is November 20, 2023. About Johnson & Johnson At... Read More

2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4%* and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of 9.0%* Earnings per share (EPS) of $1.69 increasing 4.3% and adjusted EPS of $2.66 increasing by 19.3%* Company is increasing 2023 full-year guidance midpoints for sales 5 and adjusted EPS NEW BRUNSWICK, N.J. / Oct 17, 2023 / Business Wire... Read More

NEW BRUNSWICK, N.J. / Sep 18, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 17 th to review third-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional... Read More

Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and determination to improve the health of people worldwide NEW BRUNSWICK, N.J. / Sep 14, 2023 / Business Wire / For more than 135 years, Johnson & Johnson (the “Company”) (NYSE: JNJ) has provided health care products and solutions to people worldwide. Now, with its exclusive focus on healthcare... Read More

Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and Adjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine Company expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of 12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at... Read More

NEW BRUNSWICK, N.J. / Aug 23, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023.... Read More

NEW BRUNSWICK, N.J. / Aug 22, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 21 st Annual Global Healthcare Conference at the Sheraton New York Hotel in New York on Wednesday, September 13 th . Joaquin Duato, Chairman of the Board and Chief Executive Officer and John Reed, Executive Vice President Pharmaceuticals R&D will represent the Company in a session scheduled at 10:10 a.m.... Read More

NEW BRUNSWICK, N.J. / Aug 21, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the... Read More

NEW BRUNSWICK, N.J. / Aug 16, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced the final exchange ratio for its previously announced split-off exchange offer to Johnson & Johnson shareholders to exchange their shares of Johnson & Johnson for shares of common stock of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) currently held by Johnson & Johnson. For each share of Johnson & Johnson common stock that is validly... Read More

NEW YORK , Aug. 9, 2023 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) will be added to the S&P 500 effective prior to the open on a date to be announced conditioned upon the successful completion of a voluntary exchange offer being conducted by S&P 500 & S&P 100 constituent Johnson & Johnson (NYSE: JNJ). Johnson & Johnson announced its intention to split off at least 80.1% of Kenvue shares it owns through a voluntary exchange... Read More

NEW BRUNSWICK, N.J. / Aug 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2023 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Thursday, September 7 th . Ashley McEvoy, EVP, Worldwide Chairman, MedTech along with executives from Abiomed will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). This conference call will be... Read More

SKILLMAN, N.J. / Jul 24, 2023 / Business Wire / Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced that it intends to file a Form S-4 Registration Statement today with the Securities and Exchange Commission (the “SEC”) in connection with Johnson & Johnson’s (NYSE: JNJ) proposed offer to exchange up to 1,533,830,450 shares of Kenvue common stock that it owns, representing 80.1% of the total outstanding shares of Kenvue common... Read More

Separation enhances Company focus on Pharmaceutical and MedTech Research & Development to deliver innovative and differentiated health outcomes Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for shares of Kenvue Provides Johnson & Johnson shareholders with option for a tax-free exchange for U.S. Federal income tax purposes NEW BRUNSWICK, N.J. / Jul 24, 2023 /... Read More

2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* Earnings per share (EPS) of $1.96 increasing 8.9% and adjusted EPS of $2.80 increasing by 8.1%* Company is increasing 2023 full-year guidance midpoints for adjusted operational sales excluding COVID-19 Vaccine and adjusted... Read More

NEW BRUNSWICK, N.J. / Jul 10, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the UBS MedTech, Tools and Genomics Summit on Tuesday, August 15 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Celine Martin, Company Group Chairman Cardiovascular & Specialty Solutions Group (CSS), Anthony (Tony) Long, VP, Clinical Research, Medical Affairs, Preclinical Research and Jasmina... Read More

NEW BRUNSWICK, N.J. / Jun 06, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Thursday, July 20 th to review second-quarter results. Joaquin Duato, Chairman of the Board and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. Investors and other... Read More

NEW BRUNSWICK, N.J. / May 10, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global Therapeutic Head, Oncology, will represent the Company in a session scheduled at 4:20... Read More

NEW BRUNSWICK, N.J. & SKILLMAN, N.J. / May 03, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue’s upsized initial public offering (“IPO”) of 172,812,560 shares of Kenvue’s common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up... Read More

NEW BRUNSWICK, N.J. / Apr 25, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and... Read More

NEW BRUNSWICK, N.J. / Apr 24, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (“IPO”) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600... Read More

Leadership committee seeks to bring resolution to decade-long legal battle ST. LOUIS , April 21, 2023 /PRNewswire/ -- Lawyers representing approximately 55,000 plaintiffs in the litigation against Johnson & Johnson (NYSE: JNJ) over its cancer-causing talcum powder products have formed an Ad Hoc Committee to support an $8.9 billion deal that would end a decade-long legal battle against the pharmaceutical giant. To view the ad... Read More

2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%* 2023 First-Quarter basic loss per share of ($0.03) decreasing 101.6% due to a special one-time charge, with adjusted earnings per share (EPS) of $2.68 increasing by 0.4%* Company is increasing 2023 full-year guidance midpoints for adjusted operational sales and adjusted operational EPS... Read More

LTL’s Reorganization Plan Has Significant Support From Claimants The Plan Includes LTL’s Present Value Commitment of $8.9 Billion Payable Over 25 Years For Complete Resolution NEW BRUNSWICK, N.J. / Apr 04, 2023 / Business Wire / Johnson & Johnson (NYSE:JNJ) (the Company) today announced that its subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a... Read More

NEW BRUNSWICK, N.J. / Mar 15, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18 th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional... Read More

BEERSE, Belgium / Mar 15, 2023 / Business Wire / The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The first-in-class antiviral, which was shown to be safe and well tolerated in a Phase 1 first-in-human clinical... Read More

NEW BRUNSWICK, N.J. / Mar 08, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson, priced an offering of the following series of senior unsecured notes in an aggregate principal amount of $7.75 billion (each series of notes collectively, the “Notes”): Principal Coupon Maturity Date $750,000,000 5.500% Senior Notes due 2025... Read More

NEW BRUNSWICK, N.J. / Feb 14, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors. “I am excited to welcome Dr. Paula Johnson to Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Paula is an impressive leader, physician-scientist,... Read More

NEW BRUNSWICK, N.J. / Feb 14, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global HealthCare Conference on Tuesday, March 14 th , at the Loews Miami Beach Hotel, Miami Beach, Florida. Aldo Denti, Company Group Chairman DePuy Synthes and Peter Menziuso, Company Group Chairman, Vision will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). This live audio webcast... Read More

NEW BRUNSWICK, N.J. / Feb 13, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the Company) today announced the appointment of John Reed, M.D., Ph.D., to the Company’s Executive Committee as Executive Vice President of Pharmaceuticals, R&D. Dr. Reed previously served as Executive Vice President, Global Head of Research and Development for Sanofi and brings more than 35 years of biomedical research leadership to the... Read More

NEW BRUNSWICK, N.J. / Feb 02, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 43 rd Annual HealthCare Conference on Tuesday, March 7 th , at the Boston Marriott Copley Place, Boston, MA. Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time). This live audio webcast will be available to investors... Read More

2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%* 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%* 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by... Read More

Johnson & Johnson (NYSE: JNJ) will participate in the SVB Securities Global Biopharma Conference on Wednesday, February 15 th . Biljana Naumovic, Worldwide Vice President, Oncology and Peter Lebowitz, Global Therapeutic Head, Oncology will represent the Company in a virtual session scheduled at 1:00 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the... Read More

Broadens MedTech Portfolio with World Leading Solutions for Heart Recovery Strengthens Position in High-Growth MedTech Segments Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment. “We are... Read More

Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured at the 2022 ASH Annual Meeting 1 BEERSE, BELGIUM, Dec. 10, 2022 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf (ready to use) bispecific T-cell engager antibody. 1 , 2 , 3... Read More

Alex Gorsky to Step Down After 30-Year Career at Johnson & Johnson NEW BRUNSWICK, N.J.--( BUSINESS WIRE )-- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Chief Executive Officer, Mr. Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step down from his role as Executive Chairman following a brief... Read More

Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson’s Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction NEW BRUNSWICK, N.J. & DANVERS,... Read More